Shares of Tectonic Therapeutic (NASDAQ:TECX – Get Free Report) saw strong trading volume on Tuesday . 35,556 shares were traded during trading, an increase of 52% from the previous session’s volume of 23,456 shares.The stock last traded at $15.90 and had previously closed at $15.90.
Analyst Upgrades and Downgrades
TECX has been the topic of several research reports. Piper Sandler started coverage on shares of Tectonic Therapeutic in a report on Wednesday, June 26th. They issued an “overweight” rating and a $76.00 target price on the stock. TD Cowen initiated coverage on Tectonic Therapeutic in a report on Monday, June 24th. They issued a “buy” rating for the company.
Check Out Our Latest Report on TECX
Tectonic Therapeutic Stock Performance
Tectonic Therapeutic (NASDAQ:TECX – Get Free Report) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.15) earnings per share for the quarter. On average, equities analysts forecast that Tectonic Therapeutic will post -5 EPS for the current fiscal year.
About Tectonic Therapeutic
Avrobio, Inc is a bio-technology company. It develops step-change cell and gene therapies for the treatment of cancer and rare disease. The company operates primarily in the United States and Canada. Avrobio, Inc is based in MA, United States.
Featured Stories
- Five stocks we like better than Tectonic Therapeutic
- How to Calculate Return on Investment (ROI)
- Celebrate July 4th with These Red, White, & Blue Chip Stocks
- What is a Secondary Public Offering? What Investors Need to Know
- AbbVie Stock: A Perfect Dip for Investors to Buy
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Forget NVIDIA: Super Micro Computer Stock Leads in Momentum
Receive News & Ratings for Tectonic Therapeutic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tectonic Therapeutic and related companies with MarketBeat.com's FREE daily email newsletter.
